In October 2025, Citest Diagnostics released the Calprotectin Semi-quantitative Rapid Test (Feces) -- a sophisticated chromatographic immunoassay developed exclusively for professional in vitro diagnostic use. This innovative test enables the semi-quantitative detection of calprotectin in human fecal samples, serving as a valuable tool to aid in the diagnosis of inflammatory gastrointestinal conditions. With a defined cut-off range of 50–200 μg/g, it effectively helps clinicians differentiate between inflammatory and non-inflammatory bowel diseases, supporting more informed treatment decisions.
Based on advanced chromatographic immunoassay technology, the Calprotectin Rapid Test ensures accurate and efficient assessment of gastrointestinal inflammation. A standout feature is its ability to deliver reliable results in just 5 minutes, significantly accelerating the diagnostic workflow. This rapid turnaround time enables healthcare providers to promptly initiate appropriate interventions and improve patient management, particularly in time-sensitive clinical scenarios.
The test offers four major advantages: it enhances diagnostic precision through a dual cut-off system that reduces the likelihood of misdiagnosis; it delivers results within 5 minutes, optimizing clinical workflow efficiency; it demonstrates broad clinical utility across diverse healthcare settings from primary care clinics to specialized laboratories; and it ensures consistent and dependable performance with excellent stability, guaranteeing reproducible and clinically trustworthy outcomes.
In summary, Citest's Calprotectin Semi-quantitative Rapid Test (Feces) represents a significant advancement in gastrointestinal inflammation diagnostics by integrating accuracy, speed, versatility and reliability. By addressing the need for efficient and dependable calprotectin monitoring, this test enhances clinical decision-making and supports improved patient management strategies. This product launch underscores Citest Diagnostics' continued commitment to developing innovative diagnostic solutions that protect public health and improve patient outcomes globally, reinforcing their position as a leader in the in vitro diagnostics industry.
